We publish our pricing. £1,500 a month per molecule. See it here →
Thiazide-type diuretic

Indapamide prescribing across the NHS.

Indapamide is the thiazide-type diuretic NICE has preferred since 2011, and the data shows the guidance worked: 6.2m items a year and rising while bendroflumethiazide falls. As a pair, the two lines are one of the cleanest examples of guideline-driven substitution in English prescribing.

Scorecard, last 12 months
Items
6.2m
dispensed in the last 12 months
Spend
£30.9m
at NIC, last 12 months
Year on year
+2.4% +2.4%
vs the 12 months before
Latest month
July 2026
most recent NHSBSA release
Key facts · plain English

The NHS in England dispensed 6,219,184 prescription items of Indapamide in the 12 months to July 2026, across primary care and hospitals.

Spending on Indapamide over those 12 months was £30.9m at net ingredient cost, the list price of what was dispensed before any discounts.

Items were up 2.4% on the previous 12 months.

99% of Indapamide volume moved through primary care and 1% through hospital pharmacies.

Indapamide is the largest of 7 chemical substances in Thiazides and related diuretics (BNF 2.2.1), by items dispensed.

Among Integrated Care Boards, NHS North East and North Cumbria ICB dispensed the highest volume of Indapamide.

Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.

National trend · since 2020
Indapamide, England: monthly items and spend
Items per month (teal) and spend, £ (orange)
items £ 2020-11 2023-09 2026-07 1 Jul 2026 · Price concession granted1 Jun 2026 · Price concession granted1 Mar 2026 · Price concession granted1 Jan 2026 · Price concession granted1 Dec 2025 · Price concession granted1 Nov 2025 · Price concession granted1 Oct 2025 · Price concession granted1 Sep 2025 · Price concession granted1 Aug 2025 · Price concession granted1 Jun 2024 · Hospital framework awarded
Source: NHSBSA English Prescribing Data (OGL v3.0).

Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.

MonthItemsSpend (NIC)
July 2026 551,372 £2.9m
June 2026 529,470 £3.7m
May 2026 511,610 £2.4m
April 2026 521,397 £2.4m
March 2026 530,332 £1.7m
February 2026 481,057 £1.5m
January 2026 520,180 £1.7m
December 2025 542,254 £2.0m
November 2025 489,572 £2.3m
October 2025 529,853 £3.1m
September 2025 522,524 £3.7m
August 2025 489,563 £3.4m

The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.

Cost per item · price erosion
Indapamide, England: cost per item
Actual cost per item, primary care (£)
£7.57 £1.11 2020-11 2023-09 2026-07
Source: NHSBSA English Prescribing Data (OGL v3.0).
Market share

58.9% of its class.

Indapamide is the largest of 7 chemical substances in Thiazides and related diuretics (BNF 2.2.1), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.

See the full class picture →

Seasonality
Average items by calendar month, indexed to the year (100 = average)
120 100 80 JFMAMJJASOND

Average items by calendar month across the full history, indexed to the annual mean.

Who supplies it · dm+d register

18 suppliers hold a live indapamide listing, across 27 packs.

A A H Pharmaceuticals Ltd, Accord-UK Ltd, Alliance Healthcare (Distribution) Ltd, Almus Pharmaceuticals Ltd, Drug Tariff Special Order, HBS Healthcare Ltd, Krka UK Ltd, Medihealth (Northern) Ltd, Necessity Supplies Ltd, Niche Generics Ltd, Phoenix Healthcare Distribution Ltd, RX Farma, Servier Laboratories Ltd, Sigma Pharmaceuticals Plc, Strides Pharma UK Ltd, Teva UK Ltd, Torrent Pharma (UK) Ltd, Zentiva Pharma UK Ltd. In the last twelve months 0 packs were listed and 1 discontinued. Every pack, its GTIN and published list price, and each week's changes are in the full report.

A listing in the NHS Dictionary of Medicines and Devices means a product may be supplied. It says nothing about sales or market share, and the list price is the reimbursement price, not what any buyer pays. Contains information from dm+d 10.1.0, published by the NHS Business Services Authority under the Open Government Licence v3.0.

Where it's prescribed · England

Indapamide across all 36 ICBs.

Every Integrated Care Board in England, shaded by how much indapamide its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.

NHS Cheshire and Merseyside ICBNHS Staffordshire and Stoke-on-Trent ICBNHS Shropshire, Telford and Wrekin ICBNHS Lincolnshire ICBNHS Leicester, Leicestershire and Rutland ICBNHS Coventry and Warwickshire ICBNHS Herefordshire and Worcestershire ICBNHS North East London ICBNHS South East London ICBNHS South West London ICBNHS Kent and Medway ICBNHS Cornwall and the Isles of Scilly ICBNHS Devon ICBNHS Somerset ICBNHS Bristol, North Somerset and South Gloucestershire ICBNHS Bath and North East Somerset, Swindon and Wiltshire ICBNHS Dorset ICBNHS Gloucestershire ICBNHS Lancashire and South Cumbria ICBNHS North East and North Cumbria ICBNHS Humber and North Yorkshire ICBNHS West Yorkshire ICBNHS Birmingham and Solihull ICBNHS Greater Manchester ICBNHS Derby and Derbyshire ICBNHS Northamptonshire ICBNHS Nottingham and Nottinghamshire ICBNHS South Yorkshire ICBNHS Black Country ICBNHS Central East ICBNHS Essex ICBNHS Hampshire and Isle of Wight ICBNHS Norfolk and Suffolk ICBNHS Surrey and Sussex ICBNHS Thames Valley ICBNHS West and North London ICB
Items per 1,000 registered patients, 12 months
FewerMore

Darker shading marks where Indapamide is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.

Data: NHSBSA English Prescribing Data (OGL v3.0). Boundaries: ONS Open Geography portal, ICBs April 2026, contains OS data © Crown copyright and database right 2026.

Zoomed out to the 7 NHS regions.

The same 12 months rolled up to NHS England's seven regions, ranked by intensity.

North WestMidlandsMidlandsMidlandsMidlandsMidlandsMidlandsLondonLondonLondonSouth EastSouth WestSouth WestSouth WestSouth WestSouth WestSouth WestSouth WestNorth WestNorth East and YorkshireNorth East and YorkshireNorth East and YorkshireMidlandsNorth WestMidlandsMidlandsMidlandsNorth East and YorkshireMidlandsEast of EnglandEast of EnglandSouth EastEast of EnglandSouth EastSouth EastLondon
Items per 1,000 registered patients, 12 months
North East and Yorkshire
Midlands
East of England
South West
North West
South East
London
Data: NHSBSA English Prescribing Data (OGL v3.0). Regions: ONS Open Geography portal, NHS England regions April 2026. Contains OS data © Crown copyright and database right 2026.
Top 3 previews

The teaser view.

Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.

Top ICBs by volume
  1. 1 NHS North East and North Cumbria ICB 384k
  2. 2 NHS West Yorkshire ICB 372k
  3. 3 NHS West and North London ICB 328k
  4. – + 33 more. See the full 36-ICB table. See all →
Fastest-growing ICBs (YoY)
  1. 1 NHS Derby and Derbyshire ICB +11.3%
  2. 2 NHS Dorset ICB +6.1%
  3. 3 NHS North East and North Cumbria ICB +4.3%
  4. – + 33 more. See every ICB, ranked. See all →
Top formulations
  1. 1 Indapamide 2.5mg tablets 69%
  2. 2 Indapamide 1.5mg modified-release tablets 31%
  3. 3 Natrilix SR 1.5mg tablets 0%
  4. – + 3 more. See every strength and pack. See all →
Primary vs secondary care
Primary 99% Hospital 1%

Split of items across NHSBSA primary care and SCMD hospital dispensing.

Deprivation · IMD 2019

Prescribing by deprivation.

Items per 1,000 registered patients by IMD decile: 1 = most deprived, 10 = least
44.2 0 12345678910

Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.

Beyond England

The devolved nations.

NationItems · 12 monthsData to
England 6.2m July 2026
Scotland 263k June 2026
Northern Ireland 133k May 2026
Wales 393k April 2026

Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.

Honesty strip

What open data won't tell you about indapamide.

Clean at national level, that is. The regional picture is messier, and items say nothing about whether existing patients were switched or just new starts redirected.

Read exactly what the data covers →

Common questions

Asked and answered.

Is indapamide prescribing rising or falling in the NHS?

Rising. England dispensed 6,219,184 items of Indapamide in the 12 months to July 2026, up 2.4% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.

How much does the NHS spend on indapamide?

£30.9m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.

Where in England is indapamide prescribed most?

By raw volume, NHS North East and North Cumbria ICB dispensed the most indapamide in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.

How up to date is this data?

This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.

Locked · Applicants only

The full breakdown.

Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.

Locked · Applicants only

See the full picture for Indapamide.

All 36 ICBs, prescribing organisations, formulation splits, Signals, and the hospital view with what trusts paid. Plus who won the NHS contract: 2 indapamide framework lines, 2 suppliers. £1,500 a month per molecule, price published, applications reviewed by a human within one working day.

No card details to apply. About one applicant in ten gets told the open data can't answer their question, before paying anything.

Apply for access → See pricing
Molecules in the same class

Related pages.

See the full molecule directory, or read about the data and pricing.

Ready when you are

Track indapamide like this, every month.

£1,500 a month per molecule. Apply and we'll pre-fill Indapamide for you.

Apply for access See a sample report